Biliary Atresia Market
DelveInsight's "Biliary Atresia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the Biliary Atresia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Biliary Atresia market report provides current treatment practices, emerging drugs, Biliary Atresia market share of the individual therapies, current and forecasted Biliary Atresia market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Biliary Atresia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Biliary Atresia market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Biliary Atresia Disease Understanding and Treatment Algorithm
The DelveInsight’s Biliary Atresia market report gives a thorough understanding of the Biliary Atresia by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.
Biliary Atresia Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for Biliary Atresia.
Biliary Atresia Treatment
It covers the details of conventional and current medical therapies available in the Biliary Atresia market for the treatment of the condition. It also provides Biliary Atresia treatment algorithms and guidelines in the United States, Europe, and Japan.
Biliary Atresia Epidemiology
The Biliary Atresia epidemiology section provides insights about the historical and current Biliary Atresia patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Biliary Atresia market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Biliary Atresia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Biliary Atresia Epidemiology
The epidemiology segment also provides the Biliary Atresia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Biliary Atresia Drug Chapters
The drug chapter segment of the Biliary Atresia report encloses the detailed analysis of Biliary Atresia marketed drugs and late-stage (Phase-III and Phase-II) Biliary Atresia pipeline drugs. It also helps to understand the Biliary Atresia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Biliary Atresia Marketed Drugs
The report provides the details of the marketed products/off-label treatments available for Biliary Atresia treatment.
Biliary Atresia Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Biliary Atresia treatment.
Biliary Atresia Market Outlook
The Biliary Atresia market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Biliary Atresia market trends by analyzing the impact of current Biliary Atresia therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Biliary Atresia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Biliary Atresia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Biliary Atresia market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Findings
This section includes a glimpse of the Biliary Atresia market in 7MM.
The United States Market Outlook
This section provides the total Biliary Atresia market size and market size by therapies in the United States.
EU-5 Countries: Market Outlook
The total Biliary Atresia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Market Outlook
The total Biliary Atresia market size and market size by therapies in Japan is also mentioned.
Biliary Atresia Drugs Uptake
This section focuses on the rate of uptake of the potential Biliary Atresia drugs recently launched in the Biliary Atresia market or expected to get launched in the market during the study period 2019-2032. The analysis covers Biliary Atresia market uptake by drugs; patient uptake by therapies; and sales of each drug.
Biliary Atresia Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Biliary Atresia market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Biliary Atresia Pipeline Development Activities
The Biliary Atresia report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Biliary Atresia key players involved in developing targeted therapeutics.
Pipeline Development Activities
The Biliary Atresia report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Biliary Atresia emerging therapies.
Reimbursement Scenario in Biliary Atresia
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current Biliary Atresia market trends, we take KOLs and SMEs ' opinion working in the Biliary Atresia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Biliary Atresia market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Biliary Atresia Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Biliary Atresia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Biliary Atresia epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Biliary Atresia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Biliary Atresia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Biliary Atresia market
Report Highlights
- In the coming years, the Biliary Atresia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Biliary Atresia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Biliary Atresia. The launch of emerging therapies will significantly impact the Biliary Atresia market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Biliary Atresia
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Biliary Atresia Report Insights
- Biliary Atresia Patient Population
- Therapeutic Approaches
- Biliary Atresia Pipeline Analysis
- Biliary Atresia Market Size and Trends
- Biliary Atresia Market Opportunities
- Impact of upcoming Biliary Atresia Therapies
Biliary Atresia Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Biliary Atresia Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Biliary Atresia Report Assessment
- Current Treatment Practices
- Unmet Needs
- Biliary Atresia Pipeline Product Profiles
- Biliary Atresia Market Attractiveness
- Market Drivers and Barriers
Key Questions
Market Insights:
- What was the Biliary Atresia drug class share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Biliary Atresia total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Biliary Atresia market size during the forecast period (2019-2032)?
- At what CAGR, the Biliary Atresia market is expected to grow by 7MM during the forecast period (2019-2032)?
- What would be the Biliary Atresia market outlook across the 7MM during the forecast period (2019-2032)?
- What would be the Biliary Atresia market growth till 2032, and what will be the resultant market Size in the year 2032?
- How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of the Biliary Atresia?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Biliary Atresia patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Biliary Atresia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Biliary Atresia?
- Out of all 7MM countries, which country would have the highest prevalent population of Biliary Atresia during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the Biliary Atresia treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Biliary Atresia in the USA, Europe, and Japan?
- What are the Biliary Atresia marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Biliary Atresia?
- How many therapies are in-development by each company for Biliary Atresia treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Biliary Atresia treatment?
- What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Biliary Atresia therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Biliary Atresia and their status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging therapies for Biliary Atresia?
- What are the global historical and forecasted market of Biliary Atresia?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Biliary Atresia market
- To understand the future market competition in the Biliary Atresia market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Biliary Atresia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Biliary Atresia market
- To understand the future market competition in the Biliary Atresia market
1. Key Insights
2. Executive Summary of Biliary Atresia
3. Competitive Intelligence Analysis for Biliary Atresia
4. Biliary Atresia: Market Overview at a Glance
4.1. Biliary Atresia Total Market Share (%) Distribution in 2019
4.2. Biliary Atresia Total Market Share (%) Distribution in 2032
5. Biliary Atresia: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Biliary Atresia Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Biliary Atresia Epidemiology Scenario in the 7MM (2019-2032)
7.4. United States Epidemiology
7.4.1. Biliary Atresia Epidemiology Scenario in the United States (2019-2032)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Biliary Atresia Epidemiology Scenario in Germany (2019-2032)
7.5.2. France Epidemiology
7.5.2.1. Biliary Atresia Epidemiology Scenario in France (2019-2032)
7.5.3. Italy Epidemiology
7.5.3.1. Biliary Atresia Epidemiology Scenario in Italy (2019-2032)
7.5.4. Spain Epidemiology
7.5.4.1. Biliary Atresia Epidemiology Scenario in Spain (2019-2032)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Biliary Atresia Epidemiology Scenario in the United Kingdom (2019-2032)
7.5.6. Japan Epidemiology
7.5.6.1. Biliary Atresia Epidemiology Scenario in Japan (2019-2032)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Biliary Atresia Treatment and Management
8.2. Biliary Atresia Treatment Algorithm
9. Biliary Atresia Unmet Needs
10. Key Endpoints of Biliary Atresia Treatment
11. Biliary Atresia Marketed Products
11.1. List of Biliary Atresia Marketed Drugs in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Biliary Atresia Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Biliary Atresia: Seven Major Market Analysis
13.1. Key Findings
13.2. Biliary Atresia Market Size in 7MM
13.3. Biliary Atresia Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Biliary Atresia Total Market Size in the United States
15.1.2. Biliary Atresia Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Biliary Atresia Total Market Size in Germany
15.3.2. Biliary Atresia Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Biliary Atresia Total Market Size in France
15.4.2. Biliary Atresia Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Biliary Atresia Total Market Size in Italy
15.5.2. Biliary Atresia Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Biliary Atresia Total Market Size in Spain
15.6.2. Biliary Atresia Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Biliary Atresia Total Market Size in the United Kingdom
15.7.2. Biliary Atresia Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Biliary Atresia Total Market Size in Japan
15.8.3. Biliary Atresia Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Biliary Atresia
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
*The table of contents is not exhaustive; the final content may vary.
List of Table
Table 1: 7MM Biliary Atresia Epidemiology (2019-2032)
Table 2: 7MM Biliary Atresia Diagnosed and Treatable Cases (2019-2032)
Table 3: Biliary Atresia Epidemiology in the United States (2019-2032)
Table 4: Biliary Atresia Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Biliary Atresia Epidemiology in Germany (2019-2032)
Table 6: Biliary Atresia Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Biliary Atresia Epidemiology in France (2019-2032)
Table 8: Biliary Atresia Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Biliary Atresia Epidemiology in Italy (2019-2032)
Table 10: Biliary Atresia Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Biliary Atresia Epidemiology in Spain (2019-2032)
Table 12: Biliary Atresia Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Biliary Atresia Epidemiology in the UK (2019-2032)
Table 14: Biliary Atresia Diagnosed and Treatable Cases in the UK (2019-2032)
Table 15: Biliary Atresia Epidemiology in Japan (2019-2032)
Table 16: Biliary Atresia Diagnosed and Treatable Cases in Japan (2019-2032)
Table 17: Drug Name, Clinical Trials by Recruitment status
Table 18: Drug Name, Clinical Trials by Zone
Table 19: Total Seven Major Market Size in USD, Million (2019-2032)
Table 20: Region-wise Market Size in USD, Million (2019-2032)
Table 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)
Table 22: United States Market Size in USD, Million (2019-2032)
Table 23: United States Market Size by Therapy in USD, Million (2019-2032)
Table 24: Germany Market Size in USD, Million (2019-2032)
Table 25: Germany Market Size by Therapy in USD, Million (2019-2032)
Table 26: France Market Size in USD, Million (2019-2032)
Table 27: France Market Size by Therapy in USD, Million (2019-2032)
Table 28: Italy Market Size in USD, Million (2019-2032)
Table 29: Italy Market Size by Therapy in USD, Million (2019-2032)
Table 30: Spain Market Size in USD, Million (2019-2032)
Table 31: Spain Market Size by Therapy in USD, Million (2019-2032)
Table 32: United Kingdom Market Size in USD, Million (2019-2032)
Table 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)
Table 34: Japan Market Size in USD, Million (2019-2032)
Table 35: Japan Market Size by Therapy in USD, Million (2019-2032)
*The list of tables is not exhaustive; the final content may vary
List of Figures
Figure 1: 7MM Biliary Atresia Epidemiology (2019-2032)
Figure 2: 7MM Biliary Atresia Diagnosed and Treatable Cases (2019-2032)
Figure 3: Biliary Atresia Epidemiology in the United States (2019-2032)
Figure 4: Biliary Atresia Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5: Biliary Atresia Epidemiology in Germany (2019-2032)
Figure 6: Biliary Atresia Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7: Biliary Atresia Epidemiology in France (2019-2032)
Figure 8: Biliary Atresia Diagnosed and Treatable Cases in France (2019-2032)
Figure 9: Biliary Atresia Epidemiology in Italy (2019-2032)
Figure 10: Biliary Atresia Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11: Biliary Atresia Epidemiology in Spain (2019-2032)
Figure 12: Biliary Atresia Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13: Biliary Atresia Epidemiology in the UK (2019-2032)
Figure 14: Biliary Atresia Diagnosed and Treatable Cases in the UK (2019-2032)
Figure 15: Biliary Atresia Epidemiology in Japan (2019-2032)
Figure 16: Biliary Atresia Diagnosed and Treatable Cases in Japan (2019-2032)
Figure 17: Drug Name, Clinical Trials by Recruitment status
Figure 18: Drug Name, Clinical Trials by Zone
Figure 19: Total Seven Major Market Size in USD, Million (2019-2032)
Figure 20: Region-wise Market Size in USD, Million (2019-2032)
Figure 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)
Figure 22: United States Market Size in USD, Million (2019-2032)
Figure 23: United States Market Size by Therapy in USD, Million (2019-2032)
Figure 24: Germany Market Size in USD, Million (2019-2032)
Figure 25: Germany Market Size by Therapy in USD, Million (2019-2032)
Figure 26: France Market Size in USD, Million (2019-2032)
Figure 27: France Market Size by Therapy in USD, Million (2019-2032)
Figure 28: Italy Market Size in USD, Million (2019-2032)
Figure 29: Italy Market Size by Therapy in USD, Million (2019-2032)
Figure 30: Spain Market Size in USD, Million (2019-2032)
Figure 31: Spain Market Size by Therapy in USD, Million (2019-2032)
Figure 32: United Kingdom Market Size in USD, Million (2019-2032)
Figure 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)
Figure 34: Japan Market Size in USD, Million (2019-2032)
Figure 35: Japan Market Size by Therapy in USD, Million (2019-2032)
*The list of figures is not exhaustive; the final content may vary
Odevixibat
Obeticholic Acid
And Many Others